Graves' disease and radioiodine therapy: Is success of ablation dependent on the choice of thyreostatic medication?

NuklearMedizin

Volumn 47, Issue 4, 2008, Pages 153-156

  Kobe, Carsten ^a   Weber, I ^a   Eschner, W ^a   Sudbrock, F ^a   Schmidt, M ^a   Dietlein, M ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antithyroid drugs; Dosimetry; Graves' disease; Hyperthyroidism; Radioiodine therapy; Thyrostatic medication

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE;

ADULT; AGED; AGRANULOCYTHEMIA; ARTHRALGIA; ARTICLE; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL DISEASE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRURITUS; RADIATION DOSE; RASH; SIDE EFFECT; THYROID FUNCTION; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; CARBIMAZOLE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; METHIMAZOLE; MIDDLE AGED; PROPYLTHIOURACIL; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 49449090408     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0145     Document Type: Article

References (24)

1. Allhabadia A, Daykin J, Sheppard MC et al. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
2. Andermann P, Schlogl S, Mader U et al. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin 2007; 46: 1-7.
3. 131I therapy of hyperthyroid diseases: Effect on cure rate evaluated by a randomized clinical trial. J Clin Endocinol Metab 2004; 89: 4439-4444.
4. Brunn J, Block U, Ruf G et al. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wschr 1981; 106: 1338-1340.
5. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for radioiodine test (version 3). Nuklearmedizin 2007; 46: 198-202.
6. Dietlein M, Dressler J, Grünwald F et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 2007; 46: 220-223.
7. Dietlein M, Moka D, Reinholz U et al. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit? Nuklearmedizin 2007; 46: 77-84.
8. 131I) therapy in graves hyperthyroidism. Arq Bras Endocrinol Metabol 2006; 50: 1088-1095.
9. Dominello A, Guinea AmReeve TS, Robinson B et al. Progressive increase in thyroid function after subtotal thyroidectomy for Graves' disease. Asian J Surg 2000; 23: 131-135.
10. Dunkelmann S, Kuenstner H, Nabavi E et al. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued anti-thyroid medication in Graves' disease. Eur J Nucl Med Mol Imaging 2007; 34: 228-236.
11. Dunkelmann S, Neumann V, Staub U et al. Results of a risk adapted and functional radioiodine therapy in Graves' disease. Nuklearmedizin 2005; 44: 238-242.
12. Eschner W, Moka D. Prä- und peritherapeutische Dosimetrie bei der Radioiodtherapie benigner Schilddrüsenerkrankungen. Der Nuklearmediziner 2004; 27: 90-97.
13. Gotthardt M, Rubner C, Bauhofer A et al. What is the best pretherapeutic dosimetry for successful radioiodine therapy of multifocal autonomy? Nuklearmedizin 2006; 45: 206-212.
14. Imseis RE, Vanmiddlesworth L, Massie JD et al. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 685-687.
15. Kobe C, Eschner W, Sudbrock F et al. Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy. Nuklearmedizin 2008; 47: 13-17.
16. Koch W, Rosa E, Knesewitsch P et al. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: What are the benefits of an electronic database? Nuklearmedizin 2005; 44: 49-55.
17. Ku CF, Lo CY, Chan WF, Kung AWC et al. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves' disease. Anz J Surg 2005; 75: 528-531.
18. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002; 29 (Suppl 2): 486-491.
19. Reinhardt MJ, Brink I, Joe AY et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect on pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002; 29: 1118-1124.
20. Sabri O, Zimny M, Schulz G et al. Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1233.
21. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectivness of raidioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004; 14: 525-530.
22. Snyder WS, Ford MR, Warner GG et al. MIRD Pamphlet No. 11: "S" Absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine 1975.
23. Walter AW, Briel M, Christ-Crain M et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. Br Med J 2007; 334: 483-484.
24. Zöphel K, Wunderlich G, Grüning T et al. Where does subclinical hypothyroidism start? Implications for definition of the upper reference limit for thyroid stimulating hormone. Nuklearmedizin 2005; 44: 56-61.